Gene editing with adeno-associated virus vector offers hope for hereditary deafness
An R75W mutation in the gap junction β2 (GJB2) gene causes severe fragmentation of gap junction plaques, connecting adjacent ...
EurekAlert!6d
New study reveals the curative potential of genome editing approach for genetic deafness
R75W mutation in the gap junction β2 (GJB2) gene causes severe fragmentation of gap junction plaques, connecting adjacent ...
GEN - Genetic Engineering and Biotechnology News13h
Digital Twin Focuses on Improving Viral Vector Production
The combination of synchronous experimental process development and digital twin core model development is among the first of its kind.
A recent gene therapy death shines a light on AAV safety
The death of a 16-year-old boy taking a gene therapy this month dealt a fresh blow to the Duchenne muscular dystrophy ...
PharmiWeb13d
Adeno Associated Virus Vector Manufacturing Market Size to Reach USD 4,829.1 Million in 2032
The Adeno Associated Virus Vector Manufacturing market, valued at USD 1,148.4 million in 2024, is expected to register robust revenue CAGR of 19.6%.Request free copy of this report:  March 14, 2025 - ...
GEN - Genetic Engineering and Biotechnology News6d
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
Medera presents updated results from gene therapy trial for heart failure
Medera announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy ...
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...